Synopsis A recent clinical study demonstrates the efficacy and safety data of adjunctive Everolimus treatment for treatment-refractory seizures associated with tuberous sclerosis complex. The present study aims to assess the efficacy and safety of adjunctive Everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in pediatric patients. This week’s “MED FACT” discusses a clinical trial from The Lancet Child & Adolescent Health, “ Adjunctive Everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial” . May 23, 2018.
Authors : Paolo Curatolo; David N Franz; John A Lawson; et. al. Key Takeaways: Adjunctive Everolimus showed an improvement in pediatric patients with treatment-refractory seizures associated with TSC. Objective: To evaluate the…
